KLLN Antikörper (C-Term)

Produktnummer ABIN655558

Dieser Kaninchen Polyklonal Antikörper detektiert spezifisch KLLN in WB. Es zeigt Reaktivität gegenüber Proben von Human. Es wurde in 3+ Publikationen zitiert.

Kurzübersicht für KLLN Antikörper (C-Term) (ABIN655558)

Target: KLLN (Killin, p53-Regulated DNA Replication Inhibitor (KLLN))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser KLLN Antikörper ist unkonjugiert

Applikation: Western Blotting (WB)

Klon: RB29503

Produktdetails anti-KLLN Antikörper

Bindungsspezifität: AA 136-163, C-Term

Aufreinigung: This antibody is purified through a protein A column, followed by peptide affinity purification.

Immunogen: This KILLIN antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 136-163 amino acids from the C-terminal region of human KILLIN.

Isotyp: Ig Fraction

Anwendungsinformationen

Applikationshinweise: WB: 1:500

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.

Haltbarkeit: 6 months

Referenzen für anti-KLLN Antikörper (ABIN655558)

Wang, Roma, Nolley, Abdul-Karim, Peehl, Eng: "Nuclear KLLN expression associates with improved relapse-free survival for prostate carcinoma." in: Endocrine-related cancer, Vol. 21, Issue 4, pp. 579-86, (2014) (PubMed).

Wang, Yu, He, Romigh, Altemus, Eng: "Activation of AR sensitizes breast carcinomas to NVP-BEZ235's therapeutic effect mediated by PTEN and KLLN upregulation." in: Molecular cancer therapeutics, Vol. 13, Issue 2, pp. 517-27, (2014) (PubMed).

Wang, He, Yu, Eng: "Androgen receptor-induced tumor suppressor, KLLN, inhibits breast cancer growth and transcriptionally activates p53/p73-mediated apoptosis in breast carcinomas." in: Human molecular genetics, Vol. 22, Issue 11, pp. 2263-72, (2013) (PubMed).

Details zu KLLN

Target: KLLN (Killin, p53-Regulated DNA Replication Inhibitor (KLLN))

Andere Bezeichnung: KILLIN

Hintergrund: DNA-binding protein involved in S phase checkpoint control-coupled apoptosis by mediating TP53/p53-induced apoptosis. Has the ability to inhibit DNA synthesis and S phase arrest coupled to apoptosis. Has affinity to both double-and single-stranded DNA.

Molekulargewicht: 19958

Gen-ID: 100144748

NCBI Accession: NP_001119521

UniProt: B2CW77